Tislelizumab after radiation to stop lung cancer from growing
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies tislelizumab (an immune therapy) given after you finish radiation or combined chemotherapy-radiation for stage III non-small cell lung cancer. It aims to keep the cancer from coming back or growing by helping your immune system stay active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that cannot be removed by surgery, or surgery is possible but you can’t tolerate or don’t want it
- Your cancer did not worsen after your radiation or chemotherapy-radiation treatment
- You were able to complete a specific prior treatment plan using standard chemotherapy (2–6 cycles) plus platinum, followed by radiation within 3 months
- Your tumor testing shows PD-L1 of at least 1%
- Your overall health score is good enough (ECOG 0–2), and you’re at least 18 years old
- Blood tests and organ function are adequate, based on results taken within 7 days before the first dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving radiation after surgery can help people with non-small cell lung cancer that has spread to multiple lymph nodes in the chest. It may offer a treatment option for those who have not had chemotherapy or immunotherapy before.
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of immunotherapy (tislelizumab) followed by surgery and radiation for people with a specific type of advanced lung cancer (N3 stage NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.